Genomic Health, Inc. (OQ:GHDX)

Business Focus: Biotechnology & Medical Research

Aug 21, 2019 08:00 am ET
New St. Gallen International Breast Cancer Guidelines Recommend Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy for Node-negative and Node-positive Early-stage Breast Cancer
REDWOOD CITY, Calif., Aug. 21, 2019 /PRNewswire/ -- Genomic Health today announced that, based on results from the prospective TAILORx1 and PlanB2 studies, the 16th St. Gallen International Breast Cancer Conference Expert Panel has recommended the Oncotype DX Breast Recurrence Score® test to guide chemotherapy treatment use for patients with hormone-receptor positive, HER-2 negative early-stage breast cancer with and without lymph node involvement (up to three positive nodes)....
Aug 15, 2019 11:18 am ET
CDOR, GHDX, TYPE, and UBNK SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Acquisitions
Rigrodsky & Long, P.A. announces that it is investigating: Condor Hospitality Trust, Inc. (NYSE: CDOR) regarding possible breaches of fiduciary duties and other violations of law related to Condor’s agreement to be acquired by NexPoint Hospitality...
Aug 14, 2019 12:16 pm ET
Shareholder Investigation Alert: Halper Sadeh LLP is Investigating Whether the Sale of These Companies is Fair to Shareholders – UBNK, TYPE, GHDX, NCI
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: United Financial Bancorp, Inc. (NASDAQ: UBNK)The investigation concerns whether United Financial and its board of directors breached...
Aug 09, 2019 08:00 pm ET
URGENT: Monteverde & Associates PC is Investigating the Following Transaction
NEW YORK, Aug. 9, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: ...
Aug 05, 2019 06:24 pm ET
Robbins Arroyo LLP: Acquisition of Genomic Health, Inc. (GHDX) by Exact Sciences Corp. (EXAS) May Not Be in Shareholders' Best Interests
Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of Genomic Health, Inc. (NASDAQ: GHDX) by Exact Sciences Corp. (NASDAQ: EXAS). On July 29, 2019, the two companies announced the signing of a definitive merger agreement pursuant to which Exact Sciences will acquire Genomic Health. Under the terms o
Aug 02, 2019 05:18 pm ET
GENOMIC HEALTH INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Genomic Health, Inc. - GHDX
NEW ORLEANS, Aug. 2, 2019 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Genomic Health, Inc. (NasdaqGS: GHDX) to Exact Sciences Corp. (NasdaqGS: EXAS).  Under the terms of the proposed transaction, shareholders of Genomic will receive only $27.50 in cash and the equivalent of $44.50 in shares of Exact Sciences for each share of Genomic that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the co...
Aug 01, 2019 12:27 pm ET
Rigrodsky & Long, P.A. Reminds Investors of Investigations of the Following Acquisitions
Rigrodsky & Long, P.A. announces that it is investigating: MidSouth Bancorp, Inc. (NYSE: MSL) regarding possible violations of law related to MidSouth’s agreement to be acquired by Hancock Whitney Corporation (NASDAQ GS: HWC) for 0.2952 shares...
Jul 31, 2019 03:33 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of the Following Acquisitions
Rigrodsky & Long, P.A. announces that it is investigating: Genomic Health, Inc. (NASDAQ GS: GHDX) regarding possible breaches of fiduciary duties and other violations of law related to Genomic Health’s agreement to be acquired by Exact Sciences...
Jul 31, 2019 01:38 pm ET
Shareholder Investigation Alert: Halper Sadeh LLP Reminds Investors That it is Investigating Whether the Sale of These Companies is Fair to Shareholders – TSS, TYPE, GHDX
Halper Sadeh LLP, a global investor rights law firm, reminds investors that it is investigating the following companies: Total System Services, Inc. (NYSE: TSS)The investigation concerns whether Total and its board of directors breached their...
Jul 29, 2019 08:00 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Investigates Genomic Health, Inc.
NEW YORK, July 29, 2019 /PRNewswire/ -- WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Genomic Health, Inc. ("Genomic Health" or the "Company") (NASDAQ: GHDX) in connection with the proposed acquisition of the Company by Exact Science Corp. ("EXAS") (NASDAQ: EXAS).  Under the terms of the agreement, Genomic Health shareholders will receive $27.50 in cash and $44.50 in EXAS shares for each GHDX share held, representing consideration of $72.00 per GHDX share.  ...
Jul 29, 2019 04:08 pm ET
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Genomic Health, Inc. (NASDAQ: GHDX) on Behalf of Genomic Shareholders and Encourages Genomic Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Genomic Health, Inc. (NASDAQ: GHDX) on behalf of Genomic shareholders concerning the proposed merger with Exact Sciences Corporation. Click here to...
Jul 29, 2019 02:42 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Genomic Health, Inc. to Exact Sciences Corp. is Fair to Shareholders
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Genomic Health, Inc. (“Genomic Health” or the “Company”) (NASDAQGS: GHDX) stock prior to July 29, 2019. You are hereby notified that...
Jul 29, 2019 12:26 pm ET
Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Genomic Health, Inc. has obtained a Fair Price in its sale to Exact Sciences Corp.
MILWAUKEE, July 29, 2019 /PRNewswire/ -- Ademi & O'Reilly, LLP is investigating Genomic (Nasdaq: GHDX) for possible breaches of fiduciary duty and other violations of the law in connection with the sale of Genomic to Exact Sciences. ...
Jul 29, 2019 11:50 am ET
Genomic Health Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Genomic Health, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – GHDX
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Genomic Health, Inc. (NASDAQ: GHDX) to Exact Sciences Corp. is fair to Genomic Health shareholders. On behalf of Genomic Health shareholders, Halper Sadeh LLP...
Jul 29, 2019 09:03 am ET
Genomic (GHDX) Alert: Johnson Fistel Investigates Proposed Sale of Genomic Health, Inc.; Are Shareholders Getting a Fair Deal?
SAN DIEGO, July 29, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Genomic Health, Inc. (NASDAQ: GHDX) ("Genomic") breached their fiduciary duties in connection with the proposed sale of the Company to Exact Sciences Corp. ("Exact Sciences")....
Jul 29, 2019 07:01 am ET
Genomic Health Reports 19% Revenue Growth and Record Profit in Second Quarter 2019, Raises Full-Year Guidance
REDWOOD CITY, Calif., July 29, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter ended June 30, 2019.  The company's earnings call and webcast previously scheduled for Thursday, August 1 will now occur Monday, July 29 at 8 a.m. eastern time as a joint transaction call with Exact Sciences Corp....
Jul 29, 2019 07:00 am ET
Exact Sciences and Genomic Health to Combine, Creating Leading Global Cancer Diagnostics Company
MADISON, Wis. and REDWOOD CITY, Calif., July 29, 2019 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) and Genomic Health, Inc. (NASDAQ: GHDX) today announced that the companies have entered into a definitive agreement under which Exact Sciences will combine with Genomic Health for $72.00 per share in a cash and stock transaction valued at $2.8 billion. The transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to be completed by the end of 2019....
Jul 25, 2019 08:00 am ET
Genomic Health to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 1, 2019
REDWOOD CITY, Calif., July 25, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Thursday, August 1 at 4:30 p.m. Eastern Time to discuss its second quarter 2019 financial results. The call and webcast will follow the release of the second quarter financial results after market close....
Jul 23, 2019 06:17 pm ET
Genomic Health Set to Join S&P SmallCap 600
NEW YORK, July 23, 2019 /PRNewswire/ -- Genomic Health Inc. (NASD: GHDX) will replace Electronics For Imaging Inc. (NASD: EFII) in the S&P SmallCap 600 effective prior to the open of trading on Monday, July 29. Siris Capital Group LLC acquired Electronics For Imaging in a deal that closed today....
May 07, 2019 04:05 pm ET
Genomic Health Reports First Quarter 2019 Financial Results and Recent Business Progress
REDWOOD CITY, Calif., May 7, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter ended March 31, 2019....
Apr 30, 2019 08:00 am ET
Genomic Health to Announce First Quarter 2019 Financial Results and Host Conference Call on Tuesday, May 7, 2019
REDWOOD CITY, Calif., April 30, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Tuesday, May 7 at 4:30 p.m. Eastern Time to discuss its first quarter 2019 financial results. The call and webcast will follow the release of the first quarter financial results after market close....
Mar 25, 2019 08:00 am ET
New Long-term Outcomes Data Presented at St. Gallen International Breast Cancer Conference Reinforce TAILORx Treatment Paradigm and Standard of Care Use for Oncotype DX Breast Recurrence Score® Test
REDWOOD CITY, Calif., March 25, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that new data presented at the 16th St. Gallen International Breast Cancer Conference in Vienna reinforce the utility of the Oncotype DX Breast Recurrence Score® test to optimize chemotherapy recommendations in patients with early-stage breast cancer with or without lymph node involvement....
Mar 25, 2019 07:10 am ET
Report: Exploring Fundamental Drivers Behind ON Semiconductor, Pilgrim's Pride, Merck & Co., Healthcare Services Group, Genomic Health, and Spectrum Pharmaceuticals — New Horizons, Emerging Trends, an
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ON Semiconductor Corporation (NASDAQ:ON), Pilgrim's Pride Corporation...
Feb 20, 2019 03:05 pm ET
Genomic Health Reports Record 2018 Fourth Quarter and Year-end Financial Results and Provides 2019 Financial Guidance
REDWOOD CITY, Calif., Feb. 20, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter and year ended December 31, 2018....
Feb 13, 2019 07:00 am ET
Genomic Health to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on Wednesday, February 20, 2019
REDWOOD CITY, Calif., Feb. 13, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Wednesday, February 20 at 4:30 p.m. Eastern Time to discuss its fourth quarter and year-end 2018 financial results. The call and webcast will follow the release of the fourth quarter and year-end financial results after market close....
Feb 05, 2019 07:00 am ET
Oncotype DX® Genomic Prostate Score® Established as First Genomic Test with Prospective Validation for Predicting Adverse Pathology in Newly Diagnosed Patients
REDWOOD CITY, Calif., Feb. 5, 2019 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of results from a multi-center, prospective validation study of the Oncotype DX® Genomic Prostate Score® (GPS™) test in newly diagnosed men with clinically low-risk prostate cancer who elected immediate radical prostatectomy after receiving the test. Published in Urology, the study results prospectively validated the GPS test as an independent predictor of adverse pathology at the time of surgery as a measure of disease aggressiveness for men with clinically low- or intermed...
Jan 08, 2019 07:30 am ET
Investor Expectations to Drive Momentum within National Beverage, Rexford Industrial Realty, OUTFRONT Media, Genomic Health, Zumiez, and Timken Steel — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of National Beverage Corp. (NASDAQ:FIZZ), Rexford Industrial Realty, Inc....
Jan 07, 2019 07:00 am ET
Genomic Health Marks More than 1 Million Patients Worldwide Who Have Benefited from Oncotype DX Testing in Personalizing Cancer Treatment Decisions to Improve Outcomes
REDWOOD CITY, Calif., Jan. 7, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that, in collaboration with physicians around the world, it has delivered more than 1 million Oncotype DX® tests to cancer patients worldwide since it made its first test available to patients in 2004. To date, more than 53,000 physicians across 90 countries have used Oncotype DX to optimize treatment decisions for their breast, prostate and colon cancer patients. Use of Oncotype DX is helping deliver on the promise of precision medicine by improving outcomes for cancer patients around the ...
Dec 19, 2018 07:00 am ET
NICE Expands Recommendation for the Oncotype DX Breast Recurrence Score® Test to More Patients with Early-Stage Breast Cancer Within the United Kingdom
REDWOOD CITY, Calif., Dec. 19, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the National Institute for Health and Care Excellence (NICE) in the United Kingdom has issued its updated guidance again recommending the Oncotype DX Breast Recurrence Score® test for use in clinical practice to guide adjuvant chemotherapy treatment decisions for certain patients with early-stage breast cancer. Further, NICE expanded its recommendation to include patients with micrometastases, indicating that some cancer cells have spread to the lymph nodes....
Dec 18, 2018 07:00 am ET
Genomic Health to Present at the 37th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Dec. 18, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that Kim Popovits, chairman of the board, chief executive officer and president, will present at the 37th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Monday, January 7, 2019 at 11:30 a.m. Pacific Time....
Dec 10, 2018 07:00 am ET
Multiple Oncotype DX Study Presentations at the 2018 San Antonio Breast Cancer Symposium Reinforce Real-world Value of the Oncotype DX Breast Recurrence Score® Test in Patients Regardless of Age or Ra
REDWOOD CITY, Calif., Dec. 10, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced results from multiple Oncotype DX Breast Recurrence Score® (RS) presentations at the 2018 San Antonio Breast Cancer Symposium® (SABCS), reinforcing the value of the Oncotype DX® test in optimizing treatment and outcomes in patients with both node-negative and node-positive early-stage breast cancer. ...
Dec 03, 2018 03:51 pm ET
Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla™ Oncotype DX® Genomic Prostate Score® Test
REDWOOD CITY, Calif. and MECHELEN, Belgium, Dec. 3, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX), the world's leading provider of genomic-based diagnostic tests and Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announced they have expanded their exclusive collaboration into the field of urology with the development of an in vitro diagnostic (IVD) version of the Oncotype DX® Genomic Prostate Score® (GPS™) test on Biocartis' Idylla™ platform and potentially additional cancer tests that can be performed locally by laboratory partne...
Nov 29, 2018 07:00 am ET
New Analysis of NSABP Randomized B-20 Study Confirms Patients with Oncotype DX Breast Recurrence Score® Results Greater Than 25 Have Life-saving Substantial Benefit from Chemotherapy, Reinforcing the
REDWOOD CITY, Calif., Nov. 29, 2018 /PRNewswire/ --Genomic Health, Inc. (NASDAQ: GHDX)  and the NSABP Foundation today announced the publication of positive results from a new analysis of the NSABP-led B-20 study reconfirming that the Oncotype DX Breast Recurrence Score® test predicts which patients with early-stage, HER2-negative breast cancer will benefit from chemotherapy....
Nov 28, 2018 07:20 am ET
Market Trends Toward New Normal in Genomic Health, Beacon Roofing Supply, Cronos Group, Aimmune Therapeutics, OGE Energy, and Spartan Motors — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Genomic Health, Inc. (NASDAQ:GHDX), Beacon Roofing Supply, Inc....
Nov 19, 2018 07:00 am ET
Genomic Health Announces Presentation of Two Large Studies at the 2018 San Antonio Breast Cancer Symposium, Reinforcing Real-world Value of the Oncotype DX Breast Recurrence Score® Test
REDWOOD CITY, Calif., Nov. 19, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present results from two large studies of the Oncotype DX Breast Recurrence Score® test at the 2018 San Antonio Breast Cancer Symposium® (SABCS), which will be held December 4-8. The study findings reinforce the value of the Oncotype DX® test in optimizing treatment and outcomes in patients with both node-negative and node-positive early-stage breast cancer. Presentations include: ...
Nov 08, 2018 07:00 am ET
Genomic Health to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum
REDWOOD CITY, Calif., Nov. 8, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present at the 2018 Canaccord Genuity Medical Technologies and Diagnostics Forum in New York City on Thursday, November 15, 2018 at 9:30 a.m. Eastern Time....
Nov 06, 2018 03:05 pm ET
Genomic Health Announces Record Revenue and Profit in Third Quarter 2018 Financial Results; Raises Full Year Guidance
REDWOOD CITY, Calif., Nov. 6, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter ended September 30, 2018....
Oct 30, 2018 08:00 am ET
Genomic Health to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 6, 2018
REDWOOD CITY, Calif., Oct. 30, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ:  GHDX) today announced that the company will host a conference call and webcast on Tuesday, November 6 at 4:30 p.m. Eastern Time to discuss its third quarter 2018 financial results. The call and webcast will follow the release of the third quarter financial results after market close....
Oct 29, 2018 08:00 am ET
Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castrate Resistant Prostate Cancer Effective December 1
SAN DIEGO and REDWOOD CITY, Calif., Oct. 29, 2018 /PRNewswire/ -- Epic Sciences, Inc. (Epic) and Genomic Health, Inc. (Nasdaq: GHDX) announced today that Palmetto GBA, a Medicare Administrative Contractor that assesses molecular diagnostic technologies, has issued a positive final local coverage determination (LCD) for the Oncotype DX® AR-V7 Nucleus Detect™ test. The final LCD recommends Medicare coverage for use of the test effective December 10, 2018, throughout the United States to help determine which patients with metastatic castrate resistant prostate cancer (mCRPC) may benefit from co...
Oct 22, 2018 08:00 am ET
Genomic Health Announces Multiple Studies Reinforcing Value of Oncotype DX® Tests in Guiding Treatment for Breast and Prostate Cancer Patients
REDWOOD CITY, Calif., Oct. 22, 2018 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from multiple studies of its Oncotype DX® tests highlighting their value in optimizing treatment for patients with various stages of breast and prostate cancer. The findings, presented at the ESMO 2018 Congress in Munich, Germany, demonstrated that the Oncotype DX tests identify patients who will or will not benefit from a specific treatment. ...
Oct 18, 2018 08:15 am ET
New Research Coverage Highlights Altair Engineering, Genomic Health, Seres Therapeutics, REV Group, MACOM Technology Solutions, and New Mountain Finance — Consolidated Revenues, Company Growth, and Ex
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Altair Engineering Inc. (NASDAQ:ALTR), Genomic Health, Inc. (NASDAQ:GHDX),...
Oct 09, 2018 04:15 pm ET
New NCCN Breast Cancer Guidelines Elevate Oncotype DX Breast Recurrence Score® as the Only Preferred Multi-gene Test to Predict Chemotherapy Treatment
REDWOOD CITY, Calif., Oct. 9, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that its Oncotype DX Breast Recurrence Score® test has been categorized as the only "preferred" test for chemotherapy treatment decision-making for patients with node-negative early-stage breast cancer by the National Comprehensive Cancer Network (NCCN) in its 2018 guidelines for invasive breast cancer chemotherapy treatment. The only test elevated to "strongly consider" guideline inclusion with level 1 evidence, Oncotype DX continues to be distinguished as the only genomic test predictive ...
Sep 28, 2018 08:00 am ET
New Published Data and Recent Positive Private Payor Coverage Decisions Underscore Value and Utility of the Oncotype DX Genomic Prostate Score® (GPS™) Test
REDWOOD CITY, Calif., Sept. 28, 2018 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of real-world clinical evidence demonstrating that use of the Oncotype DX Genomic Prostate Score® (GPS™) test resulted in significantly higher use of active surveillance compared to no testing. Results of this new analysis, published in Reviews in Urology, build on the original study by using propensity score matching and coarsened exact matching to increase the confidence in the impact of GPS testing in clinical practice. To date, the collective published clinical utility...
Sep 12, 2018 08:00 am ET
Epic Sciences Announces Completion of $52 Million Series E Financing
SAN DIEGO, Sept. 12, 2018 /PRNewswire/ -- Epic Sciences (Epic) announced today that the company has completed a $52 million Series E financing led by Blue Ox Healthcare Partners, with participation by Deerfield Management and Varian (NYSE: VAR). Existing investors, including Altos Capital Partners, Genomic Health, Inc., Domain Associates, VI Ventures, Alexandria Venture Investments, and Sabby Management, also participated in the financing. ...
Sep 07, 2018 08:00 am ET
German Health Technology Assessment Body (IQWiG) Concludes Only Oncotype DX® has Sufficient Evidence to Guide Breast Cancer Adjuvant Chemotherapy Decisions Based on Landmark TAILORx Study Results
REDWOOD CITY, Calif., Sept. 7, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced the publication of an updated assessment of breast cancer gene expression profiling tests by the German Institute for Quality and Efficiency in Health Care (IQWiG). In its analysis, IQWiG concluded that, based on results from the TAILORx study, the Oncotype DX Breast Recurrence Score® test can support patients with primary node-negative, hormone-receptor positive, HER2-negative breast cancer in the decision for or against chemotherapy. ...
Aug 24, 2018 08:25 am ET
Report: Exploring Fundamental Drivers Behind HomeStreet, Schnitzer Steel Industries, OraSure Technologies, Genomic Health, Benchmark Electronics, and Stoneridge — New Horizons, Emerging Trends, and Up
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of HomeStreet, Inc. (NASDAQ:HMST), Schnitzer Steel Industries, Inc....
Aug 02, 2018 04:05 pm ET
Genomic Health Announces Second Quarter 2018 Financial Results and Reports Recent Business Progress
REDWOOD CITY, Calif., Aug. 2, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter ended June 30, 2018....
Jul 26, 2018 08:00 am ET
Genomic Health to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 2, 2018
REDWOOD CITY, Calif., July 26, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Thursday, August 2 at 4:30 p.m. Eastern Time to discuss its second quarter 2018 financial results. The call and webcast will follow the release of the second quarter financial results after market close....
Jun 28, 2018 11:00 am ET
Blood Test Predicts Treatment Response and Survival for Patients with Metastatic Prostate Cancer
NEW YORK and SAN DIEGO, June 28, 2018 /PRNewswire/ -- An international team of researchers from Memorial Sloan Kettering Cancer Center (MSK), Epic Sciences, The Institute of Cancer Research, UK, and London Health Sciences Centre, Canada, have shown that a blood test can identify patients with metastatic castration resistant prostate cancer (mCRPC) who may live longer if they switch from targeted androgen receptor-signaling inhibitor (ARSi) therapy, such as enzalutamide and abiraterone, to taxane-based chemotherapy. This independent, multicenter, blinded study is one of the first studies to v...
Jun 19, 2018 08:25 am ET
Research Report Identifies Synaptics, Ethan Allen Interiors, Urban Edge Properties, RPM International, Genomic Health, and United Community Banks with Renewed Outlook — Fundamental Analysis, Calculati
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Synaptics Incorporated (NASDAQ:SYNA), Ethan Allen Interiors Inc....
Jun 03, 2018 07:30 am ET
Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Demonstrate the Oncotype DX Breast Recurrence Score® Test Definitively Identifies the 70% of Women with Early-stage Br
REDWOOD CITY, Calif., June 3, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, successfully defined the benefit of chemotherapy in early-stage breast cancer patients with Oncotype DX Breast Recurrence Score® results of 11 to 25. The long-awaited results of the TAILORx study, the largest ever breast cancer treatment trial, sponsored by the National Cancer Institute (NCI), and led by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), provided definitive evidence that the Oncotype DX Breast R...
May 30, 2018 08:00 am ET
Genomic Health to Present at Jefferies 2018 Global Healthcare Conference
REDWOOD CITY, Calif., May 30, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present at the Jefferies 2018 Global Healthcare Conference in New York City on Wednesday, June 6, 2018 at 8:30 a.m. Eastern Time....
May 21, 2018 08:00 am ET
New Data Reinforce Positive Impact of the Oncotype DX® Genomic Prostate Score™ Test in Guiding Treatment Decisions
REDWOOD CITY, Calif., May 21, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced results from two new studies demonstrating the positive impact of the Oncotype DX® Genomic Prostate Score™ (GPS™) test on risk assessment for better treatment decisions in clinically low-risk prostate cancer patients in real-world practice. The data were presented at the 2018 American Urological Association (AUA) Annual Meeting in San Francisco, May 18-21. ...
May 09, 2018 08:00 am ET
Genomic Health to Present at Bank of America Merrill Lynch 2018 Health Care Conference
REDWOOD CITY, Calif., May 9, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present at the Bank of America Merrill Lynch 2018 Health Care Conference in Las Vegas on Wednesday, May 16, 2018 at 3:00 p.m. Pacific Time....
May 02, 2018 04:05 pm ET
Genomic Health Announces First Quarter 2018 Financial Results and Reports Recent Business Progress
REDWOOD CITY, Calif., May 2, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter ended March 31, 2018....
Apr 26, 2018 08:00 am ET
Large Independent Study Using the Oncotype DX® Test Accepted for Presentation at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
REDWOOD CITY, Calif., April 26, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) has been informed of the acceptance of the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, for presentation by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). The trial will be presented during the Plenary Session at the 2018 American Society of Clinical Oncology Annual Meeting, which will take place June 1-5 at McCormick Place in Chicago. Following are presentation details:...
Apr 25, 2018 08:00 am ET
Genomic Health to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 2, 2018
REDWOOD CITY, Calif., April 25, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Wednesday, May 2 at 4:30 p.m. Eastern Time to discuss its first quarter 2018 financial results. The call and webcast will follow the release of the first quarter financial results after market close....
Apr 24, 2018 07:35 am ET
Consolidated Research: 2018 Summary Expectations for AeroVironment, PS Business Parks, Genomic Health, Digi International, Sensient Technologies, and PolyOne — Fundamental Analysis, Key Performance In
NEW YORK, April 24, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AeroVironment, Inc. (NASDAQ:AVAV), PS Business Parks,...
Mar 30, 2018 08:00 am ET
Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Cas
SAN DIEGO and REDWOOD CITY, Calif., March 30, 2018 /PRNewswire/ -- Epic Sciences, Inc. (Epic) and Genomic Health, Inc. (Nasdaq: GHDX) announced today that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued a draft local coverage determination (LCD) for the Oncotype DX® AR-V7 Nucleus Detect™ test. The draft LCD recommends Medicare coverage for use of the test throughout the United States to help determine which patients with metastatic castration-resistant prostate cancer (mCRPC) may benefit from androgen receptor signaling inh...
Mar 15, 2018 08:00 am ET
Landmark TAILORx Results Aid in Assessing the Effect of Chemotherapy in Women with Early-stage Breast Cancer and Oncotype DX Breast Recurrence Score® Results of 11 to 25
REDWOOD CITY, Calif., March 15, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) was informed by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) that the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, has achieved sufficient information to render a conclusion regarding the effect of chemotherapy in early-stage breast cancer patients with Recurrence Score® results of 11 to 25.  This primary study group represents approximately 100,000 women diagnosed each year in the United States alone. ECOG-ACRIN will be submitting the results as a late-breaking abstract fo...
Mar 08, 2018 07:00 am ET
Genomic Health Announces 2017 Fourth Quarter and Year-end Financial Results, Provides 2018 Financial Outlook
REDWOOD CITY, Calif., March 8, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter and year ended December 31, 2017....
Feb 28, 2018 08:15 am ET
Consolidated Research: 2018 Summary Expectations for Genomic Health, Worthington Industries, BMC Stock, Alexander & Baldwin, ACI Worldwide, and La-Z-Boy — Fundamental Analysis, Key Performance Indicat
NEW YORK, Feb. 28, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Genomic Health, Inc. (NASDAQ:GHDX), Worthington Industries,...
Feb 26, 2018 07:00 am ET
Genomic Health Expands Offering to Prostate Cancer Patients with Launch of Oncotype DX® AR-V7 Nucleus Detect™ Test to Predict Treatment Response in Metastatic Disease
REDWOOD CITY, Calif., Feb. 26, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced the U.S. commercial launch of the Oncotype DX® AR-V7 Nucleus Detect™ test. The first and only liquid biopsy test of its kind, the Oncotype DX AR-V7 Nucleus Detect test was developed by Epic Sciences to help prolong the lives of men with metastatic castration-resistant prostate cancer (mCRPC) by accurately detecting a splice variant of the androgen receptor protein (AR-V7) in the nucleus of circulating tumor cells (CTCs). Knowledge of a patient's AR-V7 status enables physicians to confident...
Feb 22, 2018 07:00 am ET
Genomic Health to Announce Fourth Quarter and Year-End 2017 Financial Results and Host Conference Call on Thursday, March 8, 2018
REDWOOD CITY, Calif., Feb. 22, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Thursday, March 8 at 8:30 a.m. Eastern Time to discuss its fourth quarter and year-end 2017 financial results. The call and webcast will follow the release of the fourth quarter and year-end financial results before the market opens....
Feb 05, 2018 07:00 am ET
Oncotype DX® Genomic Prostate Score™ Test Increases Use of Active Surveillance by 30 Percent in Low-risk Patients, Resulting in Greater Adherence to Guideline-based Care
REDWOOD CITY, Calif., Feb. 5, 2018 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of real-world clinical evidence demonstrating that use of the Oncotype DX® Genomic Prostate Score™ (GPS™) test resulted in significantly higher use of active surveillance at six and 12 months compared to no testing within the same time period. Results of this large, independently conducted study, published in Reviews in Urology, bring the collective published clinical utility evidence to four studies in nearly 8,300 men, demonstrating the actionable impact of the GPS test in...
Dec 28, 2017 08:30 am ET
Analysis: Positioning to Benefit within Genomic Health, Worthington Industries, Rambus, OMNOVA Solutions, CAI International, and Rudolph Technologies — Research Highlights Growth, Revenue, and Consoli
NEW YORK, Dec. 28, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Genomic Health, Inc. (NASDAQ:GHDX), Worthington Industries,...
Dec 21, 2017 07:00 am ET
Genomic Health to Present at the 36th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Dec. 21, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits, chairman of the board, chief executive officer and president, will present at the 36th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Monday, January 8, 2018 at 9:00 a.m. Pacific Time. ...
Dec 11, 2017 07:00 am ET
Genomic Health Presents New Data Demonstrating Value of Oncotype DX® to Optimize Breast Cancer Outcomes and Reduce Treatment Burden throughout Disease Continuum
REDWOOD CITY, Calif., Dec. 11, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced results of 10 studies that reinforce the unmatched value of the Oncotype DX Breast Recurrence Score® test and Oncotype DX® DCIS Score™ test in optimizing patient treatment across the breast cancer disease continuum. The data were recently presented at the 2017 San Antonio Breast Cancer Symposium (SABCS). ...
Dec 06, 2017 07:00 am ET
Genomic Health Announces Research Collaboration with Janssen Pharmaceuticals to Evaluate the Oncotype DX® Genomic Prostate Score™ Test for Potential Drug Development
REDWOOD CITY, Calif., Dec. 6, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced a multi-year research collaboration agreement with Janssen Pharmaceuticals to evaluate the Oncotype DX Genomic Prostate Score™ (GPS™) test for their prostate cancer drug pipeline.  As part of the agreement, Genomic Health will test samples from Janssen studies to examine the association of GPS results with clinical outcomes....
Nov 30, 2017 07:00 am ET
Genomic Health Announces Presentation of 10 Oncotype DX® Studies at the 2017 San Antonio Breast Cancer Symposium Demonstrating Test's Unique Value in Predicting Neoadjuvant Treatment Benefit and Guidi
REDWOOD CITY, Calif., Nov. 30, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present 10 Oncotype DX® studies at the 40th San Antonio Breast Cancer Symposium (SABCS), which is being held December 5-9, 2017. Presentation highlights include:...
Nov 28, 2017 07:00 am ET
Genomic Health and Cleveland Diagnostics Announce Strategic Collaboration to Develop and Commercialize New Prostate Cancer Tests
REDWOOD CITY, Calif. and CLEVELAND, Nov. 28, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX), the world's leading provider of genomic-based diagnostic tests, and Cleveland Diagnostics, Inc., a biotechnology company focused on developing next-generation diagnostics technology for the detection of cancers, today announced an exclusive licensing agreement to develop and commercialize new prostate cancer tests based on Cleveland Diagnostics' IsoPSA™ reagents and technology. Initial efforts under this agreement will focus on Genomic Health's development of a high-PSA (prostate-specific a...
Nov 21, 2017 07:00 am ET
Genomic Health to Present at the 29th Annual Piper Jaffray Healthcare Conference
REDWOOD CITY, Calif., Nov. 21, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present at the 29th Annual Piper Jaffray Healthcare Conference in New York City on Tuesday, November 28, 2017 at 10:30 a.m. Eastern Time....
Nov 08, 2017 04:05 pm ET
Genomic Health Announces Third Quarter 2017 Financial Results and Reports Recent Business Progress
REDWOOD CITY, Calif., Nov. 8, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter ended September 30, 2017....
Nov 01, 2017 09:00 am ET
Genomic Health to Announce Third Quarter 2017 Financial Results and Host Conference Call on Wednesday, November 8, 2017
REDWOOD CITY, Calif., Nov. 1, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Wednesday, November 8 at 4:30 p.m. Eastern Time to discuss its third quarter 2017 financial results. The call and webcast will follow the release of the third quarter financial results after market close....
Sep 13, 2017 02:00 am ET
Genomic Health and Biocartis Announce Agreement to Develop an Idylla™ IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access
REDWOOD CITY, Calif. and MECHELEN, Belgium, Sept. 13, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX), the world's leading provider of genomic-based diagnostic tests  and Biocartis Group NV (Euronext Brussels: BCART), an innovative molecular diagnostics company, today announced an exclusive agreement to develop an in vitro diagnostic (IVD) version of the Oncotype DX Breast Recurrence Score® test on Biocartis' Idylla™ platform that can be performed locally by laboratory partners and in hospitals around the world.  ...
Sep 11, 2017 09:00 am ET
Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017
REDWOOD CITY, Calif., Sept. 11, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of new data that provide additional evidence of the unmatched value of the Oncotype DX Breast Recurrence Score® test in accurately predicting outcomes in early-stage breast cancer patients. The data were presented at the 2017 European Society for Medical Oncology (ESMO) Congress in Madrid. ...
Aug 31, 2017 09:00 am ET
Genomic Health Continues to Pioneer Genomic-based Cancer Diagnostics with Multiple Presentations at ESMO 2017 Congress
REDWOOD CITY, Calif., Aug. 31, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from four Oncotype DX Breast Recurrence Score® test studies at the European Society for Medical Oncology (ESMO) 2017 Congress. The conference takes place September 8-12 at the IFEMA, Feria de Madrid, in Madrid, in partnership with the European Association for Cancer Research (EACR). Highlights from results that will be presented include:...
Aug 30, 2017 09:00 am ET
Genomic Health to Present at the 2017 Wells Fargo Healthcare Conference
REDWOOD CITY, Calif., Aug. 30, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present at the 2017 Wells Fargo Healthcare Conference in Boston on Wednesday, September 6, 2017 at 9:05 a.m. Eastern Time....
Aug 24, 2017 09:00 am ET
Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® Genomic Prostate Score™ Test in Patients with Favorable Intermediate-risk Prostate Cancer Effective October 9,
REDWOOD CITY, Calif., Aug. 24, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued a positive final Local Coverage Determination (LCD) to expand Medicare coverage of the Oncotype DX® Genomic Prostate Score™ (GPS™) test. The final LCD, recommending Medicare coverage for use of the test in qualified patients with favorable intermediate-risk prostate cancer throughout the United States, is scheduled to take effect on October 9, 2017....
Aug 01, 2017 05:05 pm ET
Genomic Health Announces Second Quarter 2017 Financial Results and Reports Recent Business Progress
REDWOOD CITY, Calif., Aug. 1, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter ended June 30, 2017....
Jul 20, 2017 09:00 am ET
Genomic Health to Announce Second Quarter 2017 Financial Results and Host Conference Call on Tuesday, August 1, 2017
REDWOOD CITY, Calif., July 20, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Tuesday, August 1 at 4:30 p.m. Eastern Time to discuss its second quarter 2017 financial results. The call and webcast will follow the release of the second quarter financial results after market close....
Jul 12, 2017 09:00 am ET
Updated St. Gallen International Breast Cancer Guidelines Reinforce Important Role of Genomic Testing in Treatment of Early Breast Cancer
REDWOOD CITY, Calif., July 12, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the 15th St. Gallen International Breast Cancer Conference Expert Panel endorsed the use of genomic tests in early-stage breast cancer and recognized the Oncotype DX Breast Recurrence Score® test for its prognostic ability as well as its value in guiding treatment decisions on adjuvant chemotherapy for patients with early-stage, endocrine-sensitive, invasive breast cancer....
Jun 02, 2017 09:00 am ET
Genomic Health Presents Data Further Demonstrating Ability of Oncotype DX® Tests to Optimize Outcomes in Patients Across Cancer Types
REDWOOD CITY, Calif., June 2, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of eight studies that provide additional evidence of the value of Oncotype DX® tests in predicting clinically meaningful endpoints and outcomes across multiple cancer types. The data from patients with invasive breast, ductal carcinoma in situ (DCIS), prostate and kidney cancers were presented in oral and poster sessions at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago....
May 30, 2017 09:00 am ET
Genomic Health Announces Presentation of Eight Oncotype DX® Studies at the 2017 American Society of Clinical Oncology Annual Meeting Reinforcing Unique Impact Across Cancer Types
REDWOOD CITY, Calif., May 30, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from eight Oncotype DX® studies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place June 2-6 at McCormick Place in Chicago. These presentations represent data across multiple tumor types including invasive breast, ductal carcinoma in situ (DCIS), prostate and renal cancers....
May 25, 2017 09:00 am ET
Genomic Health to Present at Jefferies 2017 Healthcare Conference
REDWOOD CITY, Calif., May 25, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that it will present at the Jefferies 2017 Healthcare Conference in New York City on Tuesday, June 6, 2017 at 4:30 p.m. Eastern Time....
May 13, 2017 08:00 am ET
Prospective Oncotype DX® Genomic Prostate Score™ Test Data Presented at AUA and Published in Urology Establish Test's Ability to Increase Use and Persistence on Active Surveillance in Prostate Cancer
REDWOOD CITY, Calif., May 13, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from two Oncotype DX® Genomic Prostate Score™ (GPS) test analyses based on a prospective, multi-center, 1,200-patient study. Results of one analysis, presented at the American Urological Association (AUA) 2017 Annual Meeting, prospectively validate the GPS test as an independent predictor of adverse pathology as a measure of tumor aggressiveness in men with localized prostate cancer. A second analysis, presented at AUA and published online in Urology, reinforces that the GPS test si...
May 12, 2017 01:48 pm ET
Oncotype DX® Genomic Prostate Score™ (GPS) Test Predicts 10-year Risk of Prostate Cancer-specific Death and Metastases in Patients with Early-stage Disease
REDWOOD CITY, Calif., May 12, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of new results from a large, community-based, multi-center clinical validation study conducted at Kaiser Permanente, confirming that the Oncotype DX® Genomic Prostate Score™ (GPS) test is a strong independent predictor of prostate cancer-specific death and disease progression (metastases) at 10 years in men with localized prostate cancer across all National Comprehensive Cancer Network (NCCN) clinical risk groups....
May 10, 2017 09:00 am ET
Genomic Health to Present at Bank of America Merrill Lynch 2017 Health Care Conference
REDWOOD CITY, Calif., May 10, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that it will present at the Bank of America Merrill Lynch 2017 Health Care Conference in Las Vegas on Wednesday, May 17, 2017 at 11:20 a.m. Pacific Time....
May 09, 2017 05:05 pm ET
Genomic Health Announces First Quarter 2017 Financial Results and Reports Recent Business Progress
REDWOOD CITY, Calif., May 9, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended March 31, 2017....
May 04, 2017 05:05 pm ET
Genomic Health Announces Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of Oncotype DX® Genomic Prostate Score™ in Patients with Favorable Intermediate-risk Prostate C
REDWOOD CITY, Calif., May 4, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued a draft local coverage determination (LCD) for the Oncotype DX® Genomic Prostate Score™ (GPS). The draft LCD recommends Medicare coverage for use of the test in qualified patients with favorable intermediate-risk prostate cancer throughout the United States. ...
May 04, 2017 09:00 am ET
Genomic Health Announces Upcoming Presentation of Four Oncotype DX® Studies Including New Validation on Its Ability to Predict Prostate Cancer-specific Death and Metastases
REDWOOD CITY, Calif., May 4, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from four new Oncotype DX® Genomic Prostate Score™ (GPS) studies will be presented at the upcoming American Urological Association (AUA) 2017 Annual Meeting, which will be held May 12-16 in Boston. With new results reporting the performance of the GPS in assessing risk and long-term outcomes in patients across various stages of prostate cancer, GPS is now the only test to provide an assessment of the current state of a man's cancer via adverse pathology, as well as his individua...
May 02, 2017 09:00 am ET
Genomic Health to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 9, 2017
REDWOOD CITY, Calif., May 2, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Tuesday, May 9 at 4:30 p.m. Eastern Time to discuss its first quarter 2017 financial results.  The call and webcast will follow the release of the first quarter financial results after market close....
Mar 30, 2017 07:45 am ET
New Research Shows Oncotype DX® Breast Cancer Test Helps Reduce Burden of Chemotherapy
Research Including Patients from Quebec Demonstrated Significant Impact of Genomic Health's Oncotype DX® in Personalizing Cancer Treatments...
Mar 29, 2017 09:00 am ET
Oncotype DX® Predicts 10-year Risk of Developing Metastatic Prostate Cancer in Low- and Intermediate-risk Patients
REDWOOD CITY, Calif., March 29, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of new results from a large multi-center validation study, which confirmed that the Oncotype DX® Genomic Prostate Score™ (GPS) is a strong independent predictor of metastases at 10 years in prostate cancer patients across all National Comprehensive Cancer Network (NCCN) clinical risk groups. The clinical validation study data were designated one of the "best posters" (abstract #352) at the 32nd Annual European Association of Urology (EAU) Congress in London....
Mar 24, 2017 09:00 am ET
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
REDWOOD CITY, Calif., March 24, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of results from the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) Registry in the peer-reviewed journal Breast Cancer Research and Treatment, reconfirming the value of the Oncotype DX Breast Recurrence Score® in guiding chemotherapy treatment decisions in certain node-positive patients. ...
Mar 20, 2017 09:00 am ET
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
REDWOOD CITY, Calif., March 20, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from 15 Oncotype DX Breast Recurrence Score® studies conducted in 12 countries that provide real-world evidence of the test's ability to change treatment decisions in breast cancer patients. The new findings, presented at the 15th St. Gallen International Breast Cancer Conference in Vienna, demonstrate the economic value of the test across multiple healthcare systems and reinforce the clinical validation, accuracy and precision of the Breast Recurrence Score™ in various early-stag...
Feb 28, 2017 08:00 am ET
Genomic Health to Present at the Cowen and Company 37th Annual Health Care Conference
REDWOOD CITY, Calif., Feb. 28, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that Kim Popovits, chairman of the board, chief executive officer and president, will present at the Cowen and Company 37th Annual Health Care Conference at the Marriot Copley Place in Boston on Tuesday, March 7, 2017 at 11:20 a.m. Eastern Time....
Feb 16, 2017 08:00 am ET
Four New Studies of Oncotype DX® Genomic Prostate Score™ (GPS) Reconfirm Value of Test in Guiding Early-stage Prostate Cancer Risk Assessment and Treatment Selection
REDWOOD CITY, Calif., Feb. 16, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) announced today the presentation of results from four studies evaluating the clinical value and utility of its Oncotype DX® Genomic Prostate Score™ (GPS) in the management of early-stage prostate cancer. Collectively, these new data highlight the test's ability to predict disease aggressiveness and refine risk stratification across National Comprehensive Cancer Network (NCCN) clinical risk groups. ...
Feb 14, 2017 04:05 pm ET
Genomic Health Announces 2016 Fourth Quarter and Year-End Financial Results, Provides 2017 Financial Outlook
REDWOOD CITY, Calif., Feb. 14, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter and year ended December 31, 2016....
Feb 07, 2017 08:00 am ET
Genomic Health to Announce Fourth Quarter and Year-End 2016 Financial Results and Host Conference Call on Tuesday, February 14, 2017
REDWOOD CITY, Calif., Feb. 7, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Tuesday, February 14 at 4:30 p.m. Eastern Time to discuss its fourth quarter and year-end 2016 financial results.  The call and webcast will follow the release of the fourth quarter and year-end financial results after market close....
Jan 03, 2017 08:00 am ET
Genomic Health to Present at the 35th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 3, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits, chairman of the board, chief executive officer and president, will present at the 35th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Monday, January 9, 2017 at 11:00 a.m. Pacific Time. ...
Dec 22, 2016 08:00 am ET
Genomic Health Announces Inclusion of Oncotype DX® in the 8th Edition of American Joint Committee on Cancer (AJCC) Criteria for Breast Cancer Staging
REDWOOD CITY, Calif., Dec. 22, 2016 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that based on unparalleled clinical evidence, the American Joint Committee on Cancer (AJCC) incorporated the Oncotype DX® test in its recently published Eighth Edition AJCC Cancer Staging Manual. Representing a rigorous, multi-disciplinary assessment, the updated criteria identify Oncotype DX as the only multi-gene test with Level I evidence to determine formal staging of breast cancer patients, based on clinical evidence in more than 63,000 patients. ...
Dec 09, 2016 08:40 am ET
Genomic Health Announces Results from Multiple Oncotype DX® Studies, Reinforcing its Impact in Delivering Precision Medicine to Breast Cancer Patients Around the World
REDWOOD CITY, Calif., Dec. 9, 2016 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced results from multiple studies demonstrating the unparalleled value of the Oncotype DX® test in individualizing breast cancer treatment decisions for patients with various stages of the disease. Presentations included two overviews of prospective outcomes data and clinical evidence supporting use of the test in early-stage breast cancer patients with node-positive and node-negative disease. Data also included new results from the Surveillance, Epidemiology, and End Results (SEER) Registry pr...
Nov 29, 2016 08:00 am ET
Genomic Health Announces Presentation of Multiple Oncotype DX® Studies at the 2016 CTRC-AACR San Antonio Breast Cancer Symposium, Reinforcing Value of Genomics in Precision Medicine
REDWOOD CITY, Calif., Nov. 29, 2016 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present seven Oncotype DX® studies at the 39th CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), which is being held December 6-10, 2016. The study findings reinforce the Company's leadership in individualizing breast cancer treatment decisions and the value of the Oncotype DX test in various stages of the disease. Presentations include:...
Nov 03, 2016 09:00 am ET
Genomic Health to Present at the Credit Suisse 25th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 3, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Brad Cole, chief operating officer and chief financial officer, will present at the Credit Suisse 25th Annual Healthcare Conference in Scottsdale, Arizona on Tuesday, November 8, 2016 at 3:30 p.m. Mountain Time. ...
Nov 01, 2016 05:05 pm ET
Genomic Health Reports Third Consecutive Quarter of Double-Digit Revenue Growth in Announcement of Third Quarter 2016 Financial Results
REDWOOD CITY, Calif., Nov. 1, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended September 30, 2016....
Nov 01, 2016 05:04 pm ET
Genomic Health Announces Positive Topline Clinical Validation Study Results Demonstrating Oncotype DX® Prostate Cancer Test Predicts Risk of Metastasis and Mortality
REDWOOD CITY, Calif., Nov. 1, 2016 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced topline results from a large clinical validation study of its biopsy-based Oncotype DX® Genomic Prostate Score™ (GPS). The study, performed in collaboration with a large integrated healthcare system, met its primary endpoint by demonstrating that the multi-gene Oncotype DX® test, assessed in prostate needle biopsy tumor tissue, is a strong predictor of the development of metastasis and prostate cancer death in patients with early-stage prostate cancer. With these new results, the Oncotype D...
Oct 26, 2016 10:15 am ET
Comprehensive Economic Analysis Published in Reviews in Urology Demonstrates Oncotype DX® Prostate Cancer Test Leads to Substantial Cost Savings and Increase in Active Surveillance
REDWOOD CITY, Calif., Oct. 26, 2016 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced publication in Reviews in Urology of a comprehensive economic analysis of the use of the Oncotype DX® Genomic Prostate ScoreTM (GPS) in low-risk prostate cancer patients. Results showed that use of the GPS results in a net savings of $2,286 per patient – including the cost of the test – by decreasing unnecessary immediate invasive treatment....
Oct 25, 2016 09:00 am ET
Genomic Health to Announce Third Quarter 2016 Financial Results and Host Conference Call on Tuesday, November 1, 2016
REDWOOD CITY, Calif., Oct. 25, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Tuesday, November 1 at 4:30 p.m. Eastern Time to discuss its third quarter 2016 financial results. The call and webcast will follow the release of the third quarter financial results after market close....
Oct 11, 2016 09:00 am ET
Genomic Health Presents Robust Analytical Validation Study Results of Oncotype SEQ™ Liquid Biopsy Mutation Panel
REDWOOD CITY, Calif., Oct. 11, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from its successfully completed analytical validation study of Oncotype SEQ™ Liquid Select, which demonstrated that this liquid biopsy mutation panel is highly sensitive, specific and reproducible. To provide transparent and clinically meaningful performance standards, the analytical performance for Oncotype SEQ is reported on a per-sample basis rather than a per-DNA base measure. The data were presented at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhage...
Oct 10, 2016 09:00 am ET
Multiple Oncotype DX® Presentations at ESMO 2016 Congress Reinforce Its Unique Clinical Utility with Prospective Outcomes Results in Over 63,000 Breast Cancer Patients
REDWOOD CITY, Calif., Oct. 10, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from eight Oncotype DX® Breast Recurrence Score™ (RS) presentations at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark, highlighting superior clinical evidence in identifying which patients with node-negative and node-positive invasive breast cancer should be treated with chemotherapy. Specifically, prospective clinical outcomes in more than 7,400 patients with node-positive invasive breast cancer from two independent studies show excellent sur...
Sep 28, 2016 09:00 am ET
Genomic Health Reinforces Global Leadership in Genomic-based Diagnostics with Presentation of Nine Personalized Medicine Studies Conducted in Six Countries at ESMO 2016 Congress
REDWOOD CITY, Calif., Sept. 28, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from nine studies at the European Society for Medical Oncology (ESMO) 2016 Congress, which will take place October 7-11 at the Bella Center in Copenhagen, Denmark. The results will include:...
Aug 31, 2016 09:00 am ET
Genomic Health to Present at the 2016 Wells Fargo Healthcare Conference
REDWOOD CITY, Calif., Aug. 31, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits, Chairman of the Board, Chief Executive Officer and President, will present at the 2016 Wells Fargo Healthcare Conference at the Westin Boston Waterfront Hotel in Boston on Wednesday, September 7, 2016 at 4:05 p.m. Eastern Time....
Aug 02, 2016 05:05 pm ET
Genomic Health Reports Continued Double-Digit Growth in Announcement of Second Quarter 2016 Financial Results, Raises Low End of Full-Year Test and Revenue Guidance
REDWOOD CITY, Calif., Aug. 2, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended June 30, 2016....
Jul 26, 2016 09:00 am ET
Genomic Health to Announce Second Quarter 2016 Financial Results and Host Conference Call on Tuesday, August 2, 2016
REDWOOD CITY, Calif., July 26, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Tuesday, August 2 at 4:30 p.m. Eastern Time to discuss its second quarter 2016 financial results.  The call and webcast will follow the release of the second quarter financial results after market close....
Jul 07, 2016 01:05 am ET
Genomic Health and Epic Sciences Announce Strategic Collaboration to Deliver Novel AR-V7 Liquid Biopsy Test to Predict Treatment Response in Metastatic Prostate Cancer
REDWOOD CITY, Calif. and SAN DIEGO, July 7, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) and Epic Sciences, Inc. today announced an exclusive agreement to commercialize Epic Sciences' novel AR-V7 liquid biopsy test in the United States through Genomic Health's world-class commercial channel. The blood-based test detects the V7 variant of the androgen receptor protein (AR-V7) in the nucleus of circulating tumor cells (CTC) – information that can help guide treatment selection in patients with metastatic castration-resistant prostate cancer (mCRPC). ...
Jun 14, 2016 09:00 am ET
Genomic Health Launches Oncotype SEQ™ Liquid Biopsy Mutation Panel
REDWOOD CITY, Calif., June 14, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the commercial launch of Oncotype SEQ™ Liquid Select, the first of several non-invasive liquid biopsy tests that the company plans to deliver through its Oncotype IQ™ Genomic Intelligence Platform. Oncotype SEQ is a blood-based test that uses next-generation sequencing to identify and assess actionable genomic alterations in a panel of 17 select genes to inform the treatment of stage IV solid tumors, including lung, breast, colon, melanoma, ovarian, and gastrointestinal stromal tumors....
Jun 08, 2016 05:05 pm ET
Nature Partner Journals Publish Five-year Outcomes Results from SEER Registry Demonstrating Oncotype DX® Accurately Identifies Early-stage Breast Cancer Patients with Excellent Survival
REDWOOD CITY, Calif., June 8, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of results from the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) Registry in Nature Partner Journals Breast Cancer, a peer-reviewed journal published by Nature. Published results demonstrated, based on evidence from over 44,600 breast cancer patients, that the Oncotype DX® Breast Recurrence Score™ accurately predicts survival outcomes in patients with node-negative and node-positive disease in contemporary "real-world" clinical practic...
Jun 05, 2016 09:00 am ET
Genomic Health Announces Multiple Oncotype DX® Presentations at ASCO 2016 Showcasing Industry-leading Commitment to Bringing Precision Medicine to Cancer Patients
REDWOOD CITY, Calif., June 5, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from seven Oncotype DX® studies being presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting. Results include four new analyses from the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) Registry with more than 44,600 breast cancer patients. The SEER analyses reconfirmed through prospective outcomes data that the Oncotype DX® Breast Recurrence Score™ is an accurate predictor of five-year survival in patients with node-pos...
May 31, 2016 09:00 am ET
Genomic Health to Present at Jefferies 2016 Healthcare Conference
REDWOOD CITY, Calif., May 31, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Brad Cole, Chief Operating Officer and Chief Financial Officer, will present at the Jefferies 2016 Healthcare Conference at the Grand Hyatt in New York City on Tuesday, June 7, 2016 at 8:30 a.m. Eastern Time....
May 26, 2016 09:00 am ET
Genomic Health Announces Presentation of Seven Oncotype DX® Studies at the 2016 American Society of Clinical Oncology Annual Meeting, Including Additional Prospective Outcomes Analysis
REDWOOD CITY, Calif., May 26, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from seven Oncotype DX® studies at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place June 3-7 at McCormick Place in Chicago. The results will include:...
May 25, 2016 09:00 am ET
Genomic Health Announces Publication in Journal of Clinical Oncology Demonstrating Oncotype DX® Predicts Late Distant Recurrence in Breast Cancer
REDWOOD CITY, Calif., May 25, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the Journal of Clinical Oncology, the official journal of the American Society of Clinical Oncology (ASCO), published results from a large study confirming the ability of the Oncotype DX® Breast Recurrence Score™, in combination with quantitative estrogen-receptor (ER) expression, to accurately predict after five years of tamoxifen therapy the risk of late distant recurrence up to 15 years in patients with early-stage, hormone receptor-positive breast cancer. These findings suggest tha...
May 04, 2016 05:05 pm ET
Genomic Health Reports Double-Digit Revenue and Test Growth in Announcement of First Quarter 2016 Financial Results
REDWOOD CITY, Calif., May 4, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended March 31, 2016....
May 03, 2016 05:05 pm ET
Genomic Health to Present at Bank of America Merrill Lynch 2016 Health Care Conference
REDWOOD CITY, Calif., May 3, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits, Chairman of the Board, Chief Executive Officer and President, will present at the Bank of America Merrill Lynch 2016 Health Care Conference at the Encore at Wynn Las Vegas on Tuesday, May 10, 2016 at 3:40 p.m. Pacific Time....
Apr 27, 2016 09:00 am ET
Genomic Health to Announce First Quarter 2016 Financial Results and Host Conference Call on Wednesday, May 4, 2016
REDWOOD CITY, Calif., April 27, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Wednesday, May 4 at 4:30 p.m. Eastern Time to discuss its first quarter 2016 financial results.  The call and webcast will follow the release of the first quarter financial results after market close....
Mar 11, 2016 08:00 am ET
Genomic Health Announces Five-year Outcomes from International 'PlanB' Study Demonstrating the Clinical Utility of Oncotype DX® in Node-positive and High-risk Node-negative Breast Cancer
AMSTERDAM, March 11, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced new five-year clinical outcomes results from a large PlanB study, which was highlighted as an oral presentation at the 10th European Breast Cancer Conference (EBCC-10)1 in Amsterdam, Netherlands. The study, conducted by the West German Study Group (WSG), showed that 94 percent of early-stage breast cancer patients with Oncotype DX® Recurrence Score® results of 11 or less, who were treated with hormonal therapy alone, were disease-free five years after diagnosis. ...
Mar 09, 2016 08:00 am ET
German National Cancer Guidelines Distinguish Oncotype DX® as First and Only Multi-gene Breast Cancer Test with 1A Level of Evidence
REDWOOD CITY, Calif., March 9, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the update of the German Association of Gynecological Oncology's (AGO's) treatment guidelines to recognize Oncotype DX® as the only multi-gene breast cancer test with the highest 1A level of evidence. The AGO guidelines also reconfirmed Oncotype DX as the only multi-gene expression test validated to provide predictive information on the likelihood of chemotherapy benefit for women with early-stage, hormone-receptor positive, HER2-negative invasive breast cancer....
Mar 02, 2016 08:00 am ET
Genomic Health to Present at the Cowen and Company 36th Annual Health Care Conference
REDWOOD CITY, Calif., March 2, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Brad Cole, Chief Operating Officer and Chief Financial Officer, will present at the Cowen and Company 36th Annual Health Care Conference at the Marriot Copley Place in Boston on Wednesday, March 9, 2016 at 8:40 a.m. Eastern Time....
Feb 10, 2016 04:05 pm ET
Genomic Health Announces 2016 Financial Outlook and Provides 2015 Fourth Quarter and Year-End Financial Results
REDWOOD CITY, Calif., Feb. 10, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter and year ended December 31, 2015....
Feb 03, 2016 08:00 am ET
Genomic Health to Announce Fourth Quarter and Year-End 2015 Financial Results and Host Conference Call on Wednesday, February 10, 2016
REDWOOD CITY, Calif., Feb. 3, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Wednesday, February 10 at 4:30 p.m. Eastern Time to discuss its fourth quarter and year-end 2015 financial results. The call and webcast will follow the release of the fourth quarter and year-end financial results after market close....